Henry Meds Review
US$ 28.84
future glp 1 drugs GLP-1 Costs Explained: Managing Coverage Challenges What is the pipeline for
Description
The latest TEXAIS results in 2023 were negative with a certain trend, which might be limited by the small sample size, short treatment duration and lack of medium to long-term therapeutic evaluation
(This analysis does not include all GLP-1s covered by Medicare, only those products with more recent FDA approvals that are also approved as weight loss medications.) Spending on Ozempic alone increased substantially between 2021 and 2022
It was edited by Rebecca Ramirez
Liraglutide (Saxenda) Market Revenue Estimates and Forecasts, 2018-2030 (USD Million) 4.5
